Evidence map›Paper›PMID 29626689›Full record

ArticleWorld neurosurgery2018

Petrous Face Meningiomas: Classification, Clinical Syndromes, and Surgical Outcomes.

Stephen T Magill, Jonathan W Rick, William C Chen, David A Haase, David R Raleigh, Manish K Aghi, Philip V Theodosopoulos, Michael W McDermott

Abstract read
In one paragraph

Article in World neurosurgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Petroclival extra-adrenal myelolipoma: illustrative case.Journal of neurosurgery. Case lessons · 2025
    Article
  5. Skull Base Meningiomas.Advances in experimental medicine and biology · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Stephen T MagillDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA. Electronic address: stephen.magill@ucsf.edu.
Jonathan W RickDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
William C ChenDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
David A HaaseDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
David R RaleighDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, California, USA.
Manish K AghiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Philip V TheodosopoulosDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Michael W McDermottDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Neurological Surgery · USUniversity of California, San Francisco · US

Funding

Development of a molecular diagnostic and prognostic signature for meningiomaF32CA213944 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MAGILL, STEPHEN T · 2017 to 2017
$63k
NCI NIH HHS F32 CA213944
6 · The paper itself

Abstract

backgroundPetrous face meningiomas (PFMs) are challenging tumors because of their proximity to the cranial nerves, brainstem, and critical vasculature. The objective of this study is to present surgical outcomes and support an anatomic classification for PFM based on clinical presentation.

methodsA retrospective chart review was performed, and 51 PFMs were identified. Tumors were classified by location along the petrous face into anterior, middle, and posterior. Presentation and outcomes were analyzed with logistic regression.

resultsThe median follow-up was 31.6 months. Tumors were World Health Organization grade I (n = 50), with 1 World Health Organization grade II tumor. Location was anterior (22%), middle (14%), posterior (53%), and overlapping (12%). Median tumor diameter was 3.0 cm (range, 0.8-6.2 cm). Anterior location was associated with facial pain/numbness on presentation (P < 0.0001), middle location with hearing loss/vestibular dysfunction (P = 0.0035), and posterior with hydrocephalus (P = 0.0190), headache (P = 0.0039), and vertigo (P = 0.0265). Extent of resection was gross total (63%), near total (14%), and subtotal (25%). The observed radiographic recurrence rate was 15%. Mean progression-free survival after diagnosis was 9.1 years with 2-year, 5-year, and 10-year progression-free survival of 91.8%, 78.6%, and 62.9%, respectively. The complication rate was 27%. Age, location, and approach were not associated with complications.

conclusionsPFMs present with distinct clinical syndromes based on their location along the petrous face: anterior with trigeminal symptoms, middle with auditory/vestibular symptoms, and posterior with symptoms of mass effect/hydrocephalous. Surgical resection is associated with excellent long-term survival and a low rate of recurrence, which can be managed with radiotherapy.

Indexed as

AdultAgedAged, 80 and overCranial NervesFacial NeoplasmsFemaleFollow-Up StudiesHumansMaleMeningeal NeoplasmsMeningiomaMiddle AgedPetrous BoneRetrospective StudiesTreatment OutcomeCerebellopontine angleComplicationsMeningiomaOutcomesPetrousPetrous face

Identifiers

PMID29626689
PMCPMC5967992
OpenAlexW2795672202

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.